摘要
目的:探讨肿瘤干细胞标志物乙醛脱氢酶1(aldehy dedehydrogenase 1,ALDH1)在乳腺癌中的表达及其临床意义。方法:采用免疫组织化学染色法检测92例乳腺癌患者肿瘤组织中ALDH1蛋白的表达,并结合临床病理特征进行相关性分析和无病生存期分析。结果:ALDH1蛋白在乳腺癌组织中的阳性表达与孕激素受体(progesterone receptor,PR)和cerb-B2有关(P<0.05),与患者年龄、肿瘤大小、临床分期以及是否有淋巴结转移无关(P>0.05)。ALDH1阳性患者2年无病生存率显著低于ALDH1阴性患者(P<0.05),接受CEF方案化疗和内分泌治疗的ALDH1阳性患者2年无病生存率显著低于ALDH1阴性患者(P<0.05)。结论:ALDH1蛋白表达阳性的乳腺癌患者其无病生存率降低与耐药有关,ALDH1可作为乳腺癌预后判断的指标。
Objective：The purpose of this study is to investigate the expression of tumor stem cell marker aldehyde dehydrogenase 1 （ALDH1） in breast cancer and its clinical significance. Methods：The expression of ALDH1 protein was examined by immunohistochemical staining in 92 breast cancer tissues. The correlation analysis and disease-free survival analysis of patients was evaluated based on the clinical follow-up data. Results： Expression of ALDH1 protein had a significant correlation with progesterone receptor （PR） and cerb-B2 （P〈0.05）, but had no significant correlation with age, tumor size, clinical staging, and lymph node metastasis （P〉0.05）. The 2-year disease-free survival rate of AIDH1-positive patients was lower than that of ALDH1-negative patients （P〈0.05）. ALDH1-positive patients, who received CEF regimen chemotherapy and hormone therapy, had lower 2-year disease-free survival rate than that of ALDH1-negative patients （P〈0.05）. Conclusion ： The decreased disease-free survival rate of ALDH1-positive patients is related with drug resistance. ALDH1 could be used as an independent factor for predicting the prognosis of breast cancer.
出处
《肿瘤》
CAS
CSCD
北大核心
2009年第7期663-667,共5页
Tumor
关键词
乳腺肿瘤
干细胞
乙醛脱氢酶1
免疫组织化学
Breast neoplasms
Stem cells
Aldehyde dehydrogenase 1
Immunohistochemistry
